1 | 4R | 16/10.4 | 55 | 71 | Lymph node tissue, no malignant cells | TTF1- adenocarcinoma |
4L | 14/3.7 | 10 | 98 | TTF1- adenocarcinoma |
2 | 4R | 17/3 | 49 | 81 | TTF1+ adenocarcinoma | TTF1+ adenocarcinoma |
3 | 2R | 13/2.1 | 167 | 6 | Lymph node tissue, no malignant cells | Lymph nodes considered to be malignant on PET and CT, and a history of adenocarcinoma |
4R | 13/2.9 | 67 | 64 | Lymph node tissue, no malignant cells |
4 | 4R | 16,3/6.2 | 126 | 9 | Lymph node tissue, no malignant cells dystrophic epithelial cells | Large cell carcinoma on bronchial aspiration (right lower lobe mass) |
5 | 10R | 10/NA | 161 | 1 | No lymphocytes, no malignant cells | Tuberculosis (clinical and radiological appearance and CT response to trial therapy) |
6 | 4R | 16/NA | 144 | 18 | Lymph node tissue, no malignant cells | Sarcoma (transthoracic biopsy of a right lower lobe mass) |
7 | 21/NA | 142 | 5 | Lymph node tissue, no malignant cells |
7 | 4R | 21/10.4 | 26 | 87 | TTF1+ adenocarcinoma | TTF1+ adenocarcinoma |
8 | 11R | 20.8/5.6 | 61 | 71 | Lymph node tissue, no malignant cells | EBV-induced lymphoma (biopsy of parotid and cerebral lesions) |
9 | 4R | 29/11 | 6 | 100 | TTF1+ adenocarcinoma | TTF1+ adenocarcinoma |
10 | 4R | 30/11 | 6 | 100 | TTF1+ adenocarcinoma | TTF1+ adenocarcinoma |